Nuevolution Announces Worldwide Technology Cross-Licensing Agreement with GSK
Advertisement
Nuevolution announced the execution of a worldwide technology cross-licensing agreement with GlaxoSmithKline. The agreement relates to a number of patented technologies for rapid synthesis and DNA-tagging of hundreds of millions of chemically diverse drug-like small molecule compounds and the efficient screening of these, facilitating the identification of potent drug leads. These technologies were developed by Nuevolution and Praecis Pharmaceuticals, a wholly owned subsidiary of GlaxoSmithKline.
Under the terms of the cross-licensing agreement, GlaxoSmithKline will obtain a non-exclusive license under technology patents of Nuevolution, and Nuevolution will obtain a one time license fee and a non-exclusive license under technology patents of GlaxoSmithKline. Further details of the agreement are not disclosed.
Other news from the department business & finance
Most read news
More news from our other portals
Last viewed contents
Wuxi Rich Intelligent Equipment Co., Ltd. - Wuxi, China
How many people actually have Covid-19? - According to a study, the number of undetected cases of infected persons differs significantly in different countries
Valeant Pharmaceuticals Acquires Probiotica in Brazil
Alligator Bioscience AB appoints Sibylle Lenz as Chief Executive Officer
Quotient Bioresearch's New Radiochemistry Facility Fully Operational
Ancient rocks record first evidence for photosynthesis that made oxygen
Novel protein to prevent immune system attacks on own body - 1.2 million euros for immunology start-up
TB Alliance and BioFocus sign compound management agreement
Xceleron and Covance enter co-promotional agreement
Researchers snap giant virus in 3-D - Study demonstrates potential of future X-ray laser investigations
